Skip to main content
. 2022 Mar 17;13(3):1565–1581. doi: 10.1002/jcsm.12968

Table 1.

Animal characteristics at 32 weeks of age

Parameter Control (n = 15) HFpEF (n = 15) HFpEF + MyoMed‐205 (n = 15)
Body weight (g) 265 ± 4 559 ± 9*** 558 ± 5***
Tibia length (TL, mm) 38.2 ± 0.1 38.1 ± 0.1 38.0 ± 0.1
Heart weight/TL (mg/mm) 23.54 ± 0.31 35.44 ± 0.50*** 34.04 ± 0.35*** , §
Lung weight (wet/dry) 4.72 ± 0.07 4.18 ± 0.05*** 4.08 ± 0.03***
Serum glucose (mg/dL) 324 ± 20 572 ± 22*** 505 ± 16***
NT proBNP (pg/mL) 96.9 ± 9.4 209.0 ± 38.2* 162.8 ± 25.4
Echocardiography
LV mass (mg) 890 ± 11 1274 ± 20*** 1224 ± 17***
LVEF (%) 79.0 ± 1.1 74.3 ± 1.2** 79.6 ± 0.9 §§
LVFS (%) 52 ± 1.7 54 ± 1.3 45 ± 2.1
LVSV (μL) 441 ± 28 511 ± 17* 489 ± 19
LVEDV (μL) 555 ± 34 691 ± 25*** 605 ± 24 §§
E/e′ 21.6 ± 0.4 27.9 ± 0.7*** 23.4 ± 0.6 §§§
E/A 1.2 ± 0.1 1.4 ± 0.1** 1.2 ± 0.06 §§
LAA (mm2) 17 ± 1.1 21 ± 0.8** 22.36 ± 0.6***
LVAW (mm) 1.76 ± 0.06 2.03 ± 0.07** 2.08 ± 0.06**
LVPW (mm) 1.66 ± 0.09 2.02 ± 0.09* 2.15 ± 0.09**
LVID 6.76 ± 0.11 7.97 ± 0.19*** 7.47 ± 0.18**
Aortic valve area (mm2) 5.64 ± 0.57 3.29 ± 0.21*** 6.05 ± 0.64 §§§
Aortic valve peak pressure (mmHg) 13.39 ± 2.52 28.57 ± 3.39** 19.82 ± 1.93 §
Invasive haemodynamic measurements
Ascending aorta
SAP (mmHg) 125 ± 6 180 ± 4*** 177 ± 6**
DAP (mmHg) 95 ± 5 113 ± 3** 115 ± 4**
MAP (mmHg) 105 ± 6 136 ± 3*** 136 ± 5***
Left ventricle (LV)
LVEDP (mmHg) 15 ± 1 22 ± 1*** 16 ± 1 §§
LVESP (mmHg) 113 ± 8 165 ± 5*** 159 ± 9***
LVEDV (μL) 434 ± 29 622 ± 47** 507 ± 16
LVESV (μL) 134 ± 17 291 ± 31*** 166 ± 13 §§
dP/dt max (mmHg/s) 5791 ± 310 9864 ± 411*** 9885 ± 439***
dP/dt min (mmHg/s) −6055 ± 411 −8148 ± 323*** −8051 ± 416*
dV/dt max (μL/s) 14 972 ± 1752 15 263 ± 926 12 407 ± 1598
dV/dt min (μL/s) −12 495 ± 1344 −13 666 ± 1874 −13 296 ± 1211
LV stiffness constant betaw 0.28 ± 0.05 2.54 ± 0.67* 0.70 ± 0.14 §
Slope LV‐Ees (mmHg/μL) 0.11 ± 0.02 0.25 ± 0.06* 0.30 ± 0.05**
*

P < 0.05.

**

P < 0.01.

***

P < 0.001 vs. control.

§

P < 0.05.

§§

P < 0.01.

§§§

P < 0.001 vs. HFpEF.